Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Hepatitis

Free Subscription Articles published in Gut Retrieve available abstracts of 121 articles: HTML format

Single Articles

June 2021
1. URBAN S, Neumann-Haefelin C, Lampertico P
   Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease.
   Gut. 2021 Jun 8. pii: gutjnl-2020-323888. doi: 10.1136/gutjnl-2020-323888.
   PubMed     Abstract available
   
   
   May 2021
2. SUN J, Wu G, Pastor F, Rahman N, et al
   RNA helicase DDX5 enables STAT1 mRNA translation and interferon signalling in hepatitis B virus replicating hepatocytes.
   Gut. 2021 May 21. pii: gutjnl-2020-323126. doi: 10.1136/gutjnl-2020-323126.
   PubMed     Abstract available
   
   
   
3. JINDAL A, Vyas A, Dubey G
   Ponder of concern and long-term safety of infants from mothers with chronic hepatitis B treated with tenofovir disoproxil.
   Gut. 2021 May 5. pii: gutjnl-2021-324967. doi: 10.1136/gutjnl-2021-324967.
   PubMed    
   
   
   April 2021
4. PHAM LV, Pedersen MS, Fahnoe U, Fernandez-Antunez C, et al
   HCV genome-wide analysis for development of efficient culture systems and unravelling of antiviral resistance in genotype 4.
   Gut. 2021 Apr 8. pii: gutjnl-2020-323585. doi: 10.1136/gutjnl-2020-323585.
   PubMed     Abstract available
   
   
   March 2021
5. PAN CQ, Dai E, Duan Z, Han G, et al
   Long-term safety of infants from mothers with chronic hepatitis B treated with tenofovir disoproxil in China.
   Gut. 2021 Mar 31. pii: gutjnl-2020-322719. doi: 10.1136/gutjnl-2020-322719.
   PubMed     Abstract available
   
   
   
6. YUEN MF, Wong DK, Schluep T, Lai CL, et al
   Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment.
   Gut. 2021 Mar 12. pii: gutjnl-2020-323445. doi: 10.1136/gutjnl-2020-323445.
   PubMed     Abstract available
   
   
   February 2021
7. PENEAU C, Imbeaud S, La Bella T, Hirsch TZ, et al
   Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma.
   Gut. 2021 Feb 9. pii: gutjnl-2020-323153. doi: 10.1136/gutjnl-2020-323153.
   PubMed     Abstract available
   
   
   January 2021
8. BUKH J
   Vaccines against hepatitis C: a travel into neutralisation space.
   Gut. 2021 Jan 25. pii: gutjnl-2020-323377. doi: 10.1136/gutjnl-2020-323377.
   PubMed    
   
   
   
9. LIU CH, Chen CY, Su WW, Tseng KC, et al
   Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment.
   Gut. 2021 Jan 6. pii: gutjnl-2020-323569. doi: 10.1136/gutjnl-2020-323569.
   PubMed     Abstract available
   
   
   December 2020
10. SVICHER V, Salpini R, Piermatteo L, Carioti L, et al
    Whole exome HBV DNA integration is independent of the intrahepatic HBV reservoir in HBeAg-negative chronic hepatitis B.
    Gut. 2020 Dec 21. pii: gutjnl-2020-323300. doi: 10.1136/gutjnl-2020-323300.
    PubMed     Abstract available
    
    
    
11. BANKWITZ D, Bahai A, Labuhn M, Doepke M, et al
    Hepatitis C reference viruses highlight potent antibody responses and diverse viral functional interactions with neutralising antibodies.
    Gut. 2020 Dec 15. pii: gutjnl-2020-321190. doi: 10.1136/gutjnl-2020-321190.
    PubMed     Abstract available
    
    
    
12. YU ML, Huang CF, Wei YJ, Lin WY, et al
    Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C).
    Gut. 2020 Dec 10. pii: gutjnl-2020-323277. doi: 10.1136/gutjnl-2020-323277.
    PubMed     Abstract available
    
    
    
13. SONG S, Shi Y, Wu W, Wu H, et al
    Reticulon 3-mediated Chk2/p53 activation suppresses hepatocellular carcinogenesis and is blocked by hepatitis B virus.
    Gut. 2020 Dec 10. pii: gutjnl-2020-321386. doi: 10.1136/gutjnl-2020-321386.
    PubMed     Abstract available
    
    
    
14. KIM MA, Kim SU, Sinn DH, Jang JW, et al
    Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study.
    Gut. 2020;69:2214-2222.
    PubMed     Abstract available
    
    
    November 2020
15. KIM HL, Kim GA, Park JA, Kang HR, et al
    Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B.
    Gut. 2020 Nov 25. pii: gutjnl-2020-321309. doi: 10.1136/gutjnl-2020-321309.
    PubMed     Abstract available
    
    
    
16. TAKEUCHI M, Vidigal PT, Guerra MT, Hundt MA, et al
    Neutrophils interact with cholangiocytes to cause cholestatic changes in alcoholic hepatitis.
    Gut. 2020 Nov 19. pii: gutjnl-2020-322540. doi: 10.1136/gutjnl-2020-322540.
    PubMed     Abstract available
    
    
    
17. ZENG G, Gill US, Kennedy PTF
    Prioritisation and the initiation of HCC surveillance in CHB patients: lessons to learn from the COVID-19 crisis.
    Gut. 2020;69:1907-1912.
    PubMed    
    
    
    October 2020
18. CASTRY M, Cousien A, Supervie V, Velter A, et al
    Impact of test-and-treat and risk reduction strategies on HCV transmission among MSM living with HIV in France: a modelling approach.
    Gut. 2020 Oct 27. pii: gutjnl-2020-321744. doi: 10.1136/gutjnl-2020-321744.
    PubMed     Abstract available
    
    
    September 2020
19. LIU K, Peng P, Cai F, Huang J, et al
    Comparison of the long-term efficacy between tenofovir and entecavir in chronic hepatitis B patients.
    Gut. 2020 Sep 14. pii: gutjnl-2020-322642. doi: 10.1136/gutjnl-2020-322642.
    PubMed    
    
    
    August 2020
20. SETO WK, Liu KS, Mak LY, Cloherty G, et al
    Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation.
    Gut. 2020 Aug 5. pii: gutjnl-2020-321116. doi: 10.1136/gutjnl-2020-321116.
    PubMed     Abstract available
    
    
    July 2020
21. HOFMANN M, Thimme R
    Hepatitis B vaccine and NK cells: a new player in memory.
    Gut. 2020 Jul 15. pii: gutjnl-2020-321151. doi: 10.1136/gutjnl-2020-321151.
    PubMed    
    
    
    June 2020
22. CARGILL Z, Brown SE, Dusheiko G, Agarwal K, et al
    Risk stratification in chronic hepatitis B patients for hepatocellular carcinoma surveillance: management in migrant sub-Saharan African populations.
    Gut. 2020 Jun 30. pii: gutjnl-2020-322181. doi: 10.1136/gutjnl-2020-322181.
    PubMed    
    
    
    
23. ZOLDAN K, Hofmann M
    B protected: from vertical HCV transmission?
    Gut. 2020 Jun 30. pii: gutjnl-2020-321364. doi: 10.1136/gutjnl-2020-321364.
    PubMed    
    
    
    
24. HORVATITS T, Varwig-Janssen D, Schulze Zur Wiesch J, Lubke R, et al
    No link between male infertility and HEV genotype 3 infection.
    Gut. 2020;69:1150-1151.
    PubMed    
    
    
    April 2020
25. DE JONG YP, Liang TJ
    Stem cell-derived HCV infection systems illustrate the bright future of human hepatocyte research.
    Gut. 2020 Apr 29. pii: gutjnl-2020-321216. doi: 10.1136/gutjnl-2020-321216.
    PubMed    
    
    
    
26. LUTCKII A, Strunz B, Zhirkov A, Filipovich O, et al
    Evidence for B cell maturation but not trained immunity in uninfected infants exposed to hepatitis C virus.
    Gut. 2020 Apr 27. pii: gutjnl-2019-320269. doi: 10.1136/gutjnl-2019-320269.
    PubMed     Abstract available
    
    
    March 2020
27. SU F, Ioannou GN, Berry K
    No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir.
    Gut. 2020 Mar 30. pii: gutjnl-2019-319867. doi: 10.1136/gutjnl-2019-319867.
    PubMed     Abstract available
    
    
    
28. HUTCHINSON SJ, Valerio H, McDonald SA, Yeung A, et al
    Population impact of direct-acting antiviral treatment on new presentations of hepatitis C-related decompensated cirrhosis: a national record-linkage study.
    Gut. 2020 Mar 26. pii: gutjnl-2019-320007. doi: 10.1136/gutjnl-2019-320007.
    PubMed     Abstract available
    
    
    
29. YOUNOSSI ZM, Stepanova M, Younossi Y, Golabi P, et al
    Epidemiology of chronic liver diseases in the USA in the past three decades.
    Gut. 2020;69:564-568.
    PubMed     Abstract available
    
    
    February 2020
30. SALERNO D, Chiodo L, Alfano V, Floriot O, et al
    Hepatitis B protein HBx binds the DLEU2 lncRNA to sustain cccDNA and host cancer-related gene transcription.
    Gut. 2020 Feb 29. pii: gutjnl-2019-319637. doi: 10.1136/gutjnl-2019-319637.
    PubMed     Abstract available
    
    
    
31. CARPENTIER A, Sheldon J, Vondran FWR, Brown RJ, et al
    Efficient acute and chronic infection of stem cell-derived hepatocytes by hepatitis C virus.
    Gut. 2020 Feb 29. pii: gutjnl-2019-319354. doi: 10.1136/gutjnl-2019-319354.
    PubMed     Abstract available
    
    
    
32. BOYD A, Wandeler G
    Hepatitis D virus: is it all in the family?
    Gut. 2020 Feb 14. pii: gutjnl-2019-320549. doi: 10.1136/gutjnl-2019-320549.
    PubMed    
    
    
    
33. KAMAL F, Khan MA, Ahmed A, Nair S, et al
    Tenofovir versus entecavir in prevention of hepatocellular carcinoma and mortality in patients with chronic hepatitis B.
    Gut. 2020 Feb 10. pii: gutjnl-2019-320554. doi: 10.1136/gutjnl-2019-320554.
    PubMed    
    
    
    January 2020
34. DOLMAN GE, Kennedy PTF
    Hepatitis B reactivation: reducing the risk in patients with inflammatory bowel disease.
    Gut. 2020 Jan 30. pii: gutjnl-2019-319480. doi: 10.1136/gutjnl-2019-319480.
    PubMed    
    
    
    
35. OECHSLIN N, Moradpour D, Gouttenoire J
    Hepatitis E virus finds its path through the gut.
    Gut. 2020 Jan 8. pii: gutjnl-2019-320206. doi: 10.1136/gutjnl-2019-320206.
    PubMed    
    
    
    
36. BESOMBES C, Njouom R, Paireau J, Lachenal G, et al
    The epidemiology of hepatitis delta virus infection in Cameroon.
    Gut. 2020 Jan 6. pii: gutjnl-2019-320027. doi: 10.1136/gutjnl-2019-320027.
    PubMed     Abstract available
    
    
    
37. ZHUANG Y, Xu HC, Shinde PV, Warfsmann J, et al
    Fragile X mental retardation protein protects against tumour necrosis factor-mediated cell death and liver injury.
    Gut. 2020;69:133-145.
    PubMed     Abstract available
    
    
    
38. VERRIER ER, Weiss A, Bach C, Heydmann L, et al
    Combined small molecule and loss-of-function screen uncovers estrogen receptor alpha and CAD as host factors for HDV infection and antiviral targets.
    Gut. 2020;69:158-167.
    PubMed     Abstract available
    
    
    December 2019
39. TENG YX, Li MJ, Xiang BD, Zhong JH, et al
    Tenofovir may be superior to entecavir for preventing hepatocellular carcinoma and mortality in individuals chronically infected with HBV: a meta-analysis.
    Gut. 2019 Dec 16. pii: gutjnl-2019-320326. doi: 10.1136/gutjnl-2019-320326.
    PubMed    
    
    
    November 2019
40. LIAW YF, Jeng WJ
    Benefit of stopping finite nucleos(t)ide analogues therapy in chronic hepatitis B patients.
    Gut. 2019 Nov 29. pii: gutjnl-2019-320341. doi: 10.1136/gutjnl-2019-320341.
    PubMed    
    
    
    
41. MARION O, Lhomme S, Nayrac M, Dubois M, et al
    Hepatitis E virus replication in human intestinal cells.
    Gut. 2019 Nov 14. pii: gutjnl-2019-319004. doi: 10.1136/gutjnl-2019-319004.
    PubMed     Abstract available
    
    
    
42. SHEN DT, Goyal H, Xu HG
    Differences in delta virus hepatitis diagnosis methods and its effect on the hepatitis D prevalence.
    Gut. 2019 Nov 12. pii: gutjnl-2019-320159. doi: 10.1136/gutjnl-2019-320159.
    PubMed    
    
    
    
43. ZHAO HJ, Han QJ, Wang G, Lin A, et al
    Poly I:C-based rHBVvac therapeutic vaccine eliminates HBV via generation of HBV-specific CD8(+) effector memory T cells.
    Gut. 2019;68:2032-2043.
    PubMed     Abstract available
    
    
    October 2019
44. LEE SW, Kwon JH, Lee HL, Yoo SH, et al
    Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naive patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis.
    Gut. 2019 Oct 31. pii: gutjnl-2019-318947. doi: 10.1136/gutjnl-2019-318947.
    PubMed     Abstract available
    
    
    
45. GAVRIC A, Dezman R, Rankovic B, Ribnikar M, et al
    Nutmeg liver, fever and elevated liver enzymes in a young man.
    Gut. 2019;68:1773-1837.
    PubMed    
    
    
    September 2019
46. KAO JH, Berg T
    Nucleos(t)ide analogues in patients with chronic hepatitis B: to stop or not to stop?
    Gut. 2019 Sep 16. pii: gutjnl-2019-319648. doi: 10.1136/gutjnl-2019-319648.
    PubMed    
    
    
    August 2019
47. LIEM KS, Fung S, Wong DK, Yim C, et al
    Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study).
    Gut. 2019 Aug 28. pii: gutjnl-2019-318981. doi: 10.1136/gutjnl-2019-318981.
    PubMed     Abstract available
    
    
    
48. XIAO Y, Sun K, Duan Z, Liu Z, et al
    Quasispecies characteristic in "a" determinant region is a potential predictor for the risk of immunoprophylaxis failure of mother-to-child-transmission of sub-genotype C2 hepatitis B virus: a prospective nested case-control study.
    Gut. 2019 Aug 24. pii: gutjnl-2019-318278. doi: 10.1136/gutjnl-2019-318278.
    PubMed     Abstract available
    
    
    June 2019
49. WANG L, Zhang Z, Shu J, Zhang H, et al
    Absence of hepatitis E virus RNA in semen samples of infertile male in China.
    Gut. 2019 Jun 19. pii: gutjnl-2019-319234. doi: 10.1136/gutjnl-2019-319234.
    PubMed    
    
    
    
50. WEI Y, Li Y, Yan L, Sun C, et al
    Alterations of gut microbiome in autoimmune hepatitis.
    Gut. 2019 Jun 14. pii: gutjnl-2018-317836. doi: 10.1136/gutjnl-2018-317836.
    PubMed     Abstract available
    
    
    May 2019
51. HERZOG K, Bandiera S, Pernot S, Fauvelle C, et al
    Functional microRNA screen uncovers O-linked N-acetylglucosamine transferase as a host factor modulating hepatitis C virus morphogenesis and infectivity.
    Gut. 2019 May 10. pii: gutjnl-2018-317423. doi: 10.1136/gutjnl-2018-317423.
    PubMed     Abstract available
    
    
    
52. FAN C, Li M, Gan Y, Chen T, et al
    A simple AGED score for risk classification of primary liver cancer: development and validation with long-term prospective HBsAg-positive cohorts in Qidong, China.
    Gut. 2019;68:948-949.
    PubMed    
    
    
    
53. SCHUCH A, Salimi Alizei E, Heim K, Wieland D, et al
    Phenotypic and functional differences of HBV core-specific versus HBV polymerase-specific CD8+ T cells in chronically HBV-infected patients with low viral load.
    Gut. 2019;68:905-915.
    PubMed     Abstract available
    
    
    
54. HOOGEVEEN RC, Robidoux MP, Schwarz T, Heydmann L, et al
    Phenotype and function of HBV-specific T cells is determined by the targeted epitope in addition to the stage of infection.
    Gut. 2019;68:893-904.
    PubMed     Abstract available
    
    
    April 2019
55. SHEN DT, Ji DZ, Chen HY, Goyal H, et al
    Hepatitis D: not a rare disease anymore: global update for 2017-2018.
    Gut. 2019 Apr 9. pii: gutjnl-2019-318691. doi: 10.1136/gutjnl-2019-318691.
    PubMed    
    
    
    March 2019
56. ZHANG TY, Guo XR, Wu YT, Kang XZ, et al
    A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice.
    Gut. 2019 Mar 29. pii: gutjnl-2018-317725. doi: 10.1136/gutjnl-2018-317725.
    PubMed     Abstract available
    
    
    February 2019
57. CANDOTTI D, Assennato SM, Laperche S, Allain JP, et al
    Multiple HBV transfusion transmissions from undetected occult infections: revising the minimal infectious dose.
    Gut. 2019;68:313-321.
    PubMed     Abstract available
    
    
    January 2019
58. YUAN L, Jiang J, Liu X, Zhang Y, et al
    HBV infection-induced liver cirrhosis development in dual-humanised mice with human bone mesenchymal stem cell transplantation.
    Gut. 2019 Jan 30. pii: gutjnl-2018-316091. doi: 10.1136/gutjnl-2018-316091.
    PubMed     Abstract available
    
    
    December 2018
59. STOCKDALE AJ, Kreuels B, Henrion MRY, Giorgi E, et al
    Hepatitis D prevalence: problems with extrapolation to global population estimates.
    Gut. 2018 Dec 19. pii: gutjnl-2018-317874. doi: 10.1136/gutjnl-2018-317874.
    PubMed    
    
    
    November 2018
60. GILL US, Pallett LJ, Thomas N, Burton AR, et al
    Fine needle aspirates comprehensively sample intrahepatic immunity.
    Gut. 2018 Nov 28. pii: gutjnl-2018-317071. doi: 10.1136/gutjnl-2018-317071.
    PubMed     Abstract available
    
    
    
61. LI H, Zhai N, Wang Z, Song H, et al
    Regulatory NK cells mediated between immunosuppressive monocytes and dysfunctional T cells in chronic HBV infection.
    Gut. 2018;67:2035-2044.
    PubMed     Abstract available
    
    
    October 2018
62. WEDEMEYER H, Negro F
    Devil hepatitis D: an orphan disease or largely underdiagnosed?
    Gut. 2018 Oct 27. pii: gutjnl-2018-317403. doi: 10.1136/gutjnl-2018-317403.
    PubMed    
    
    
    
63. YANG HC, Kao JH
    Quantification of HBV core antibodies may help revisit infectious occult hepatitis B virus.
    Gut. 2018 Oct 9. pii: gutjnl-2018-317385. doi: 10.1136/gutjnl-2018-317385.
    PubMed    
    
    
    
64. LU XJ, Li XH, Yuan ZX, Sun HY, et al
    Assessment of liver fibrosis with the gamma-glutamyl transpeptidase to platelet ratio: a multicentre validation in patients with HBV infection.
    Gut. 2018;67:1903-1904.
    PubMed    
    
    
    September 2018
65. LLIBRE A, Shimakawa Y, Duffy D
    Potential utility of the Genedrive point-of-care test for HCV RNA detection.
    Gut. 2018 Sep 22. pii: gutjnl-2018-317218. doi: 10.1136/gutjnl-2018-317218.
    PubMed    
    
    
    
66. CHEN HY, Shen DT, Ji DZ, Han PC, et al
    Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis.
    Gut. 2018 Sep 18. pii: gutjnl-2018-316601. doi: 10.1136/gutjnl-2018-316601.
    PubMed     Abstract available
    
    
    August 2018
67. GAO Y, Zhou Z, Ren T, Kim SJ, et al
    Alcohol inhibits T-cell glucose metabolism and hepatitis in ALDH2-deficient mice and humans: roles of acetaldehyde and glucocorticoids.
    Gut. 2018 Aug 18. pii: gutjnl-2018-316221. doi: 10.1136/gutjnl-2018-316221.
    PubMed     Abstract available
    
    
    
68. LOCARNINI S, Raimondo G
    How infectious is the hepatitis B virus? Readings from the occult.
    Gut. 2018 Aug 1. pii: gutjnl-2018-316900. doi: 10.1136/gutjnl-2018-316900.
    PubMed    
    
    
    July 2018
69. LIM CJ, Lee YH, Pan L, Lai L, et al
    Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma.
    Gut. 2018 Jul 3. pii: gutjnl-2018-316510. doi: 10.1136/gutjnl-2018-316510.
    PubMed     Abstract available
    
    
    June 2018
70. LEMOINE M, Tillmann HL
    What is required from HCV point-of-care tests to reduce the burden of hepatitis C infection? 'Development and clinical validation of the genedrive point-of-care test for qualitative detection of hepatitis C virus'.
    Gut. 2018 Jun 29. pii: gutjnl-2018-316438. doi: 10.1136/gutjnl-2018-316438.
    PubMed    
    
    
    
71. NEGRO F
    Expanded benefits of curing the extrahepatic manifestations of HCV infection.
    Gut. 2018 Jun 5. pii: gutjnl-2018-316578. doi: 10.1136/gutjnl-2018-316578.
    PubMed    
    
    
    May 2018
72. WANG K, Lu X, Zhou H, Gao Y, et al
    Deep learning Radiomics of shear wave elastography significantly improved diagnostic performance for assessing liver fibrosis in chronic hepatitis B: a prospective multicentre study.
    Gut. 2018 May 5. pii: gutjnl-2018-316204. doi: 10.1136/gutjnl-2018-316204.
    PubMed     Abstract available
    
    
    
73. BERTOLETTI A, Kennedy PTF, Durantel D
    HBV infection and HCC: the 'dangerous liaisons'.
    Gut. 2018;67:787-788.
    PubMed    
    
    
    April 2018
74. CACOUB P, Desbois AC, Comarmond C, Saadoun D, et al
    Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis.
    Gut. 2018 Apr 27. pii: gutjnl-2018-316234. doi: 10.1136/gutjnl-2018-316234.
    PubMed     Abstract available
    
    
    
75. SHIHA G, Esmat G, Hassany M, Soliman R, et al
    Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt.
    Gut. 2018 Apr 17. pii: gutjnl-2017-315906. doi: 10.1136/gutjnl-2017-315906.
    PubMed     Abstract available
    
    
    
76. LLIBRE A, Shimakawa Y, Mottez E, Ainsworth S, et al
    Development and clinical validation of the Genedrive point-of-care test for qualitative detection of hepatitis C virus.
    Gut. 2018 Apr 3. pii: gutjnl-2017-315783. doi: 10.1136/gutjnl-2017-315783.
    PubMed     Abstract available
    
    
    
77. GILL US, Pallett LJ, Kennedy PTF, Maini MK, et al
    Liver sampling: a vital window into HBV pathogenesis on the path to functional cure.
    Gut. 2018;67:767-775.
    PubMed     Abstract available
    
    
    
78. TAN W, Xia J, Dan Y, Li M, et al
    Genome-wide association study identi fi es HLA-DR variants conferring risk of HBV-related acute-on-chronic liver failure.
    Gut. 2018;67:757-766.
    PubMed     Abstract available
    
    
    March 2018
79. LIN HH, Tseng TC, Kao JH
    Large and middle hepatitis B surface antigen: the lower the better?
    Gut. 2018 Mar 7. pii: gutjnl-2018-316030. doi: 10.1136/gutjnl-2018-316030.
    PubMed    
    
    
    February 2018
80. HEO MJ, Kim TH, You JS, Blaya D, et al
    Alcohol dysregulates miR-148a in hepatocytes through FoxO1, facilitating pyroptosis via TXNIP overexpression.
    Gut. 2018 Feb 23. pii: gutjnl-2017-315123. doi: 10.1136/gutjnl-2017-315123.
    PubMed     Abstract available
    
    
    
81. MURATA K, Asano M, Matsumoto A, Sugiyama M, et al
    Induction of IFN-lambda3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection.
    Gut. 2018;67:362-371.
    PubMed     Abstract available
    
    
    January 2018
82. CHEN CJ
    Global elimination of viral hepatitis and hepatocellular carcinoma: opportunities and challenges.
    Gut. 2018 Jan 24. pii: gutjnl-2017-315407. doi: 10.1136/gutjnl-2017-315407.
    PubMed    
    
    
    
83. IBRAHIM SH, Hirsova P, Gores GJ
    Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation.
    Gut. 2018 Jan 24. pii: gutjnl-2017-315691. doi: 10.1136/gutjnl-2017-315691.
    PubMed     Abstract available
    
    
    
84. YIGIT B, Boyle M, Ozler O, Erden N, et al
    Plasma cell-free DNA methylation: a liquid biomarker of hepatic fibrosis.
    Gut. 2018 Jan 20. pii: gutjnl-2017-315668. doi: 10.1136/gutjnl-2017-315668.
    PubMed    
    
    
    
85. KIM GA, Lim YS
    Response to: 'Prognosis of immune-tolerant phase chronic hepatitis B' by Chu and Liaw.
    Gut. 2018 Jan 13. pii: gutjnl-2017-315815. doi: 10.1136/gutjnl-2017-315815.
    PubMed    
    
    
    December 2017
86. GIERSCH K, Bhadra OD, Volz T, Allweiss L, et al
    Hepatitis delta virus persists during liver regeneration and is amplified through cell division both in vitro and in vivo.
    Gut. 2017 Dec 7. pii: gutjnl-2017-314713. doi: 10.1136/gutjnl-2017-314713.
    PubMed     Abstract available
    
    
    November 2017
87. WANG X, Yan Y, Gan T, Yang X, et al
    A trivalent HCV vaccine elicits broad and synergistic polyclonal antibody response in mice and rhesus monkey.
    Gut. 2017 Nov 27. pii: gutjnl-2017-314870. doi: 10.1136/gutjnl-2017-314870.
    PubMed     Abstract available
    
    
    
88. CHU CM, Liaw YF
    Prognosis of immune-tolerant phase chronic hepatitis B.
    Gut. 2017 Nov 25. pii: gutjnl-2017-315603. doi: 10.1136/gutjnl-2017-315603.
    PubMed    
    
    
    
89. HILLAIRE S, Kahn JE, Picone O, Cazals-Hatem D, et al
    Rare cause of abdominal pain and fever in a pregnant woman.
    Gut. 2017;66:1911-1982.
    PubMed     Abstract available
    
    
    October 2017
90. KIM GA, Lim YS, Han S, Choi J, et al
    High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B.
    Gut. 2017 Oct 21. pii: gutjnl-2017-314904. doi: 10.1136/gutjnl-2017-314904.
    PubMed     Abstract available
    
    
    September 2017
91. PFEFFERKORN M, Bohm S, Schott T, Deichsel D, et al
    Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers.
    Gut. 2017 Sep 26. pii: gutjnl-2017-313811. doi: 10.1136/gutjnl-2017-313811.
    PubMed     Abstract available
    
    
    
92. WU T, Li J, Shao L, Xin J, et al
    Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure.
    Gut. 2017 Sep 19. pii: gutjnl-2017-314641. doi: 10.1136/gutjnl-2017-314641.
    PubMed     Abstract available
    
    
    
93. 
    Erratum: The rs2296651 (S267F) variant on NTCP (SLC10A1) is inversely associated with chronic hepatitis B and progression to cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis B.
    Gut. 2017;66:1730.
    PubMed    
    
    
    August 2017
94. HUANG F, Long F, Yu W, Situ J, et al
    High prevalence of hepatitis E virus in semen of infertile male and causes testis damage.
    Gut. 2017 Aug 31. pii: gutjnl-2017-314884. doi: 10.1136/gutjnl-2017-314884.
    PubMed    
    
    
    
95. ZHANG W, Sun M, Chen G, An Y, et al
    Reassessment of gamma-glutamyl transpeptidase to platelet ratio (GPR): a large-sample, dynamic study based on liver biopsy in a Chinese population with chronic hepatitis B virus (HBV) infection.
    Gut. 2017 Aug 16. pii: gutjnl-2017-313896. doi: 10.1136/gutjnl-2017-313896.
    PubMed    
    
    
    
96. THOMPSON A, Locarnini S, Revill P
    Reply: 'More viral mutants, less HBsAg clearance? One size may not fit all'.
    Gut. 2017;66:1534-1535.
    PubMed    
    
    
    July 2017
97. PETTA S, Craxi A
    Can we prevent and modify cardiometabolic disorders by controlling HCV infection?
    Gut. 2017 Jul 13. pii: gutjnl-2017-314505. doi: 10.1136/gutjnl-2017-314505.
    PubMed    
    
    
    
98. NASSAL M
    Chronic hepatitis B: divide and conquer?
    Gut. 2017 Jul 13. pii: gutjnl-2017-314255. doi: 10.1136/gutjnl-2017-314255.
    PubMed    
    
    
    
99. TSENG TC, Yang HC, Kao JH
    More viral mutants, less HBsAg clearance? One size may not fit all.
    Gut. 2017;66:1349.
    PubMed    
    
    
    June 2017
100. LEVANDER S, Holmstrom F, Frelin L, Ahlen G, et al
     Immune-mediated effects targeting hepatitis C virus in a syngeneic replicon cell transplantation mouse model.
     Gut. 2017 Jun 23. pii: gutjnl-2016-313579. doi: 10.1136/gutjnl-2016-313579.
     PubMed     Abstract available
     
     
     
101. MAHALE P, Engels EA, Li R, Torres HA, et al
     The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection.
     Gut. 2017 Jun 20. pii: gutjnl-2017-313983. doi: 10.1136/gutjnl-2017-313983.
     PubMed     Abstract available
     
     
     
102. SUN HY, Cheng PN, Tseng CY, Tsai WJ, et al
     Favouring modulation of circulating lipoproteins and lipid loading capacity by direct antiviral agents grazoprevir/elbasvir or ledipasvir/sofosbuvir treatment against chronic HCV infection.
     Gut. 2017 Jun 14. pii: gutjnl-2017-313832. doi: 10.1136/gutjnl-2017-313832.
     PubMed     Abstract available
     
     
     
103. SCHIAVON LL, Narciso-Schiavon JL, Ferraz MLG, Silva AEB, et al
     The gamma-glutamyl transpeptidase to platelet ratio (GPR) in HBV patients: just adding up?
     Gut. 2017;66:1169-1170.
     PubMed    
     
     
     May 2017
104. THOMAS E
     Hepatitis B virus X protein: TRIMming antiviral defences in hepatocytes.
     Gut. 2017 May 5. pii: gutjnl-2017-314013. doi: 10.1136/gutjnl-2017-314013.
     PubMed    
     
     
     April 2017
105. ALLWEISS L, Volz T, Giersch K, Kah J, et al
     Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo.
     Gut. 2017 Apr 20. pii: gutjnl-2016-312162. doi: 10.1136/gutjnl-2016-312162.
     PubMed     Abstract available
     
     
     
106. RAMACHANDRAN A, Jaeschke H
     PGAM5: a new player in immune-mediated liver injury.
     Gut. 2017;66:567-568.
     PubMed    
     
     
     March 2017
107. COLPITTS CC, Tawar RG, Mailly L, Thumann C, et al
     Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape.
     Gut. 2017 Mar 30. pii: gutjnl-2016-312577. doi: 10.1136/gutjnl-2016-312577.
     PubMed     Abstract available
     
     
     
108. LAURAIN A, Kramer L, Sultanik P, Vallet-Pichard A, et al
     Mortality associated with the treatment of HCV with direct-acting antivirals.
     Gut. 2017 Mar 23. pii: gutjnl-2017-313869. doi: 10.1136/gutjnl-2017-313869.
     PubMed    
     
     
     
109. HERNAEZ R, Sola E, Moreau R, Gines P, et al
     Acute-on-chronic liver failure: an update.
     Gut. 2017;66:541-553.
     PubMed     Abstract available
     
     
     February 2017
110. ARNOLD F, Patch D, Yu D, Westbrook RH, et al
     When banding fails; investigation hails.
     Gut. 2017;66:322.
     PubMed    
     
     
     January 2017
111. LEMOINE M, Thursz M, Mallet V, Shimakawa Y, et al
     Diagnostic accuracy of the gamma-glutamyl transpeptidase to platelet ratio (GPR) using transient elastography as a reference.
     Gut. 2017;66:195-196.
     PubMed    
     
     
     September 2016
112. KUTTKAT N, Mohs A, Ohl K, Hooiveld G, et al
     Hepatic overexpression of cAMP-responsive element modulator alpha induces a regulatory T-cell response in a murine model of chronic liver disease.
     Gut. 2016 Sep 29. pii: gutjnl-2015-311119. doi: 10.1136/gutjnl-2015-311119.
     PubMed     Abstract available
     
     
     
113. DAHEIM M, Lang S, Goeser T, Steffen HM, et al
     Real-world risk score for hepatocellular carcinoma risk prediction in CHBV: a validation outside of Asia.
     Gut. 2016 Sep 26. pii: gutjnl-2016-312993. doi: 10.1136/gutjnl-2016-312993.
     PubMed    
     
     
     August 2016
114. HE GW, Gunther C, Kremer AE, Thonn V, et al
     PGAM5-mediated programmed necrosis of hepatocytes drives acute liver injury.
     Gut. 2016 Aug 26. pii: gutjnl-2015-311247. doi: 10.1136/gutjnl-2015-311247.
     PubMed     Abstract available
     
     
     July 2016
115. JENDREK ST, Gotthardt D, Nitzsche T, Widmann L, et al
     Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis.
     Gut. 2016 Jul 12. pii: gutjnl-2016-311739. doi: 10.1136/gutjnl-2016-311739.
     PubMed     Abstract available
     
     
     February 2016
116. JAMIL KM, Hydes TJ, Cheent KS, Cassidy SA, et al
     STAT4-associated natural killer cell tolerance following liver transplantation.
     Gut. 2016 Feb 17. pii: gutjnl-2015-309395. doi: 10.1136/gutjnl-2015-309395.
     PubMed     Abstract available
     
     
     
117. WIESER V, Adolph TE, Enrich B, Kuliopulos A, et al
     Reversal of murine alcoholic steatohepatitis by pepducin-based functional blockade of interleukin-8 receptors.
     Gut. 2016 Feb 8. pii: gutjnl-2015-310344. doi: 10.1136/gutjnl-2015-310344.
     PubMed     Abstract available
     
     
     October 2015
118. NAHON P, Lescat M, Layese R, Bourcier V, et al
     Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort).
     Gut. 2015 Oct 28. pii: gutjnl-2015-310275. doi: 10.1136/gutjnl-2015-310275.
     PubMed     Abstract available
     
     
     July 2015
119. KENG CT, Sze CW, Zheng D, Zheng Z, et al
     Characterisation of liver pathogenesis, human immune responses and drug testing in a humanised mouse model of HCV infection.
     Gut. 2015 Jul 6. pii: gutjnl-2014-307856. doi: 10.1136/gutjnl-2014-307856.
     PubMed     Abstract available
     
     
     June 2015
120. LEMOINE M, Shimakawa Y, Nayagam S, Khalil M, et al
     The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa.
     Gut. 2015 Jun 24. pii: gutjnl-2015-309260. doi: 10.1136/gutjnl-2015-309260.
     PubMed     Abstract available
     
     
     
121. ZHANG DY, Goossens N, Guo J, Tsai MC, et al
     A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection.
     Gut. 2015 Jun 4. pii: gutjnl-2015-309655. doi: 10.1136/gutjnl-2015-309655.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: